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The gravity of the impact of renal failure on human health is well known and as there is no speciﬁc
pharmacotherapy for renal failure, the current study was undertaken to evaluate the effect of root extract
of Azima tetracantha, an ancient medicinal plant used in Siddha and Ayurvedhic systems of medicine.
The experiment was done in glycerol-induced acute renal failure in Wistar albino rats. Thirty rats were
divided into ﬁve groups. Group 1 was given normal saline (10 ml/kg) per oral, group 2 with single dose of
hypertonic glycerol (8 ml/kg) by intramuscular injection into the hind limbs, group 3 with glycerol and
ethanolic extract of A. tetracantha root (ATR) 250 mg/kg, group 4, glycerol and ATR 500 mg/kg and group
5, 500 mg/kg ATR. Extract was given orally 60 min prior to glycerol injection. 24 h urine output, serum
creatinine, blood urea nitrogen, total proteins and albumin were measured for all the groups. Kidneys
were examined for histopathological changes.
The antioxidant activity of the extract was tested in vitro and in vivo. Rats treated with ATR showed
signiﬁcant improvement in biochemical parameters and histopathological changes compared to glycerol
treated group. The protective effect was highly signiﬁcant at 500 mg/kg. Both in vitro and in vivo assays
showed signiﬁcant antioxidant activity. The in vitro activity was comparable to vitamin-C.
The ethanolic extract of ATR has nephroprotective effect in glycerol-induced acute renal failure and the
mechanism of action could be the antioxidant effect.
Copyright © 2015, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The term acute renal failure (ARF) is currently substituted by
acute kidney injury (AKI). AKI is a reversible condition in which
there is a sudden decline in renal function, manifested by hourly/
daily/weekly elevation in serum creatinine and blood urea nitrogen
(BUN).1ology, Chettinad Hospital &
runachalam).
for Food and Biomolecules,
molecules, National Taiwan Unive
ons.org/licenses/by-nc-nd/4.0/).Different organizations such as Acute Dialysis Quality Initiative
(ADQI), Acute Kidney Injury Network (AKIN) and Kidney Disease
International Global Outcome (KDIGO) have provided different
deﬁnitions for acute kidney injury. Among these deﬁnitions of AKI,
the most acceptable one is that of KDIGO2:
AKI is any of the following3
 “Increase in serum creatinine (SCr) by ≥0.3 mg/dl (26.5 mmol/
l) within 48 h” or
 “Increase in SCr to ≥1.5 times baseline, which is known or
presumed to have occurred within the prior 7 days “ or
 “Urine volume <0.5 ml/kg/h for 6 h”.
The incidence of AKI in the community is 2147 and 4085 per
million populations per year (pmp) in developing and developedrsity. Production and hosting by Elsevier Taiwan LLC. This is an open access article
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is seen in 3.2e9.6% of hospital admissions with overall mortality of
20%e50% in ICU patients.6,7 AKI demanding renal replacement
therapy is 5e6% with a high in-hospital mortality rate of 60%. It is
estimated that nearly 2 million people die of AKI every year glob-
ally.8,9 Those who survive AKI are at a greater risk for later devel-
opment of chronic kidney disease (CKD).
The causes of AKI could be pre-renal, renal and post-renal ones.
Pre-renal failure, the commonest form of acute renal failure, is due
to decrease in renal blood ﬂow primarily as a result of hypovolemia.
It is reversible if the cause of the decreased renal blood ﬂow can be
identiﬁed and rectiﬁed before kidney damage occurs. Pre-renal
causes account for 40e70% of all AKI cases.10 Intrinsic renal cau-
ses of AKI include diseases that affect the renal parenchyma which
can be divided based on the compartment of the kidney that is
affected like tubular injury, tubulointerstitial diseases, diseases of
the renal microcirculation and glomeruli and diseases of larger
renal vessels.11 Post-renal causes of AKI are diseases associatedwith
urinary tract obstruction which account for 5% of renal failures.111.1. Management of ARF
The management of ARF is mainly supportive and in refractory
patients renal replacement therapy (RRT) may be the best option.12
RRT refers to life supporting measures which include hemodialysis,
peritoneal dialysis, hemoﬁltrationand renal transplantation. In spite
of RRT, mortality in patients with AKI remains high and this may be
due to the severity of the disease or the adverse effects of RRT.13
As there is no effective pharmacotherapy for AKI, seeking
alternative treatments becomes a necessity. Use of medicinal plants
in renal failure goes back to ancient days. More than 221 plants
have been screened for nephroprotective activity both in acute and
chronic renal failure models.14
Some of the medicinal plants such as Ocimum sanctum, Aerva
lanata, Aegle marmelos, Pongamia pinnata, Salviae radix, Ginkgo
biloba, Allium sativum, Cassia auriculata, Nigella sativa, Drynaria
fortune, Tribulus terrestris and others are reported to have neph-
roprotective activity.15
Azima tetracantha (AT) has been traditionally used for many
diseases including renal disease.16 It belongs to the family, Salva-
doraceae and known as mulchangu in Siddha and kundali in
Ayurvedha.17 Its common names are Needle brush (English),
Kantagurkamai (Hindi) and Cankakiranam (Tamil).18
AT has been reported to have antimicrobial, antifungal, anti-
inﬂammatory, analgesic, antioxidant, antipyretic, antiulcer, anti-
cancer, anti-snake venom, diuretic and hepato-protective
activities.19e23
Though AT is traditionally used for nephroprotective effect, it
has not been evaluated by either preclinical or clinical studies.
Hence this study was undertaken to evaluate its action in animal
models of renal failure.Percentage inhibition ¼ Absorbance of control Absorbance of test 100
Absorbance of control1.2. Phytochemical components in different parts of A.
tetracantha24,25
Whole plant: alkaloids e azimine, azacarpaine and carpaine.
Root and fruit: glycosides e N-methoxy-3-indolylmethyl-glu-
cosinolate, iodole glucosinolate and N-methoxy indole 3- corbinol.Root and stem: ﬂavonoids e myricetin, quercetin, rutin, iso-
rhamnetin, rhamnetin and rhamnazin.
Leaf and stem: fatty acids.
Leaf: terpinoid e friedelin.
2. Objectives
The objectives were to evaluate the nephroprotective activity of
ethanolic extract of A. tetracantha root in glycerol-induced acute
renal failure in Wistar albino rats and to ﬁnd out the probable
mechanism.
3. Materials and methods
The study was initiated after getting IAEC (Institutional Animal
Ethics Committee) approval.
3.1. Chemicals and reagents
Chemicals for in vitro and in vivo antioxidants assays were
purchased from Sigma Aldrich, New Delhi, India.
3.2. Preparation of A. tetracantha root (ATR) extract
The plant was collected from Tindivanam, Villupuram district,
Tamil Nadu, India and it was identiﬁed and authenticated by Dr.
Narasimhan, Associate Professor of Botany, Madras Christian Col-
lege, Chennai, Tamil Nadu. One kg of roots was thoroughly washed
with water and air dried under shade at room temperature for 30
days and milled into a coarse powder. The dried powder obtained
was subjected to continuous extraction with 95% v/v ethanol in
Soxhlet apparatus for 15 cycles. The extract was then dried in a ﬂash
evaporator. 55.3 g of green colored, thick and sticky residue was
obtained. It was reconstituted in 1% gum acacia before adminis-
tering to animals. The phytochemical analysis was carried out by
HPTLC studies.
3.3. Animals
Thirty healthy male Wistar albino rats weighing between 150
and 250 g were obtained from the central animal house of Chetti-
nad Hospital and Research Institute.
3.4. Study of in vitro antioxidant activity
The antioxidant activity of ATR ethanolic extract was evaluated
by 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay, nitric oxide (NO)
assay, hydrogen peroxide (H2O2) and ferric reducing antioxidant
power (FRAP) assay. Vitamin C was used as a positive control. All
assays were performed using spectrophotometer and the values
were calculated by the following formula.The ATR extract was prepared in increasing concentrations from
25 to 1600 mg/ml for all the antioxidant assays.
3.4.1. DPPH scavenging assay
One ml of ATR extract solutionwas mixed with 1 ml of ethanolic
solution of DPPH (200 mM). Another 1 ml DPPH solutionwas mixed
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of 1 ml of ethanolic solution of DPPH (200 mM) and 1 ml of ethanol
served as control. After mixing, all the solutions were incubated in
dark for 2 min and absorbance was measured at 517 nm.26 The
experiments were carried out in triplicate and the average per-
centage of inhibition was calculated by the above formula.
3.4.2. NO scavenging assay
Three ml of 10 mM sodium nitroprusside in phosphate buffer is
added to 2 ml of ATR extract and the reference compound. The
resulting solutions were then incubated at 25 C for 60 min. 5 ml of
the incubated sample and 5 ml of Griess reagent (1% sulphanila-
mide, 0.1% naphthyl ethylenediamine dihydrochloride in 2% phos-
phorous acid) were added and absorbance of the chromophore
formed was measured at 540 nm.27
3.4.3. H2O2 scavenging assay
Two ml ATR extract was mixed with 0.6 ml of 4 mM hydrogen
peroxide solution prepared in phosphate buffer (0.1 M pH 7.4) and
incubated for 10 min. The absorbance of the solution was taken at
230 nm.28
3.4.4. FRAP scavenging assay
The assay mixture contained 2.5 ml of 300 mM acetate buffer at
pH 3.6, 0.25 ml of 10 mM 2, 4,6-tripyridyl-s-triazine solution in
40 mM HCl, 0.25 ml of 20 mM ferric chloride and ATR extract at
various concentrations in 0.1 ml of methanol. The absorbance was
measured after 30 min incubation at 593 nm. FRAP values were
measured by comparing the absorption change in the test mixture
with that obtained from increasing concentrations of Fe3þ.29
3.5. Acute toxicity study
Acute oral toxicity study was conducted as per OECD-423
guidelines. Female rats (150e200 g), nulliparous and non-
pregnant were randomly distributed to four groups (1e4) of 3
each. The rats were fasted overnight and given orally 5, 50, 300 and
2000 mg/kg of ATR extract. They were observed continuously for
the ﬁrst 2 h and hourly for the next 6 h and at 24, 48, and 72 h for
general behavior, convulsions and mortality.
No mortality or toxicity was observed up to the dose of
2000 mg/kg. Hence, the drug was found to be safe. Based on the
acute toxicity studies 250 and 500 mg/kg of the ethanolic extract
were used for the current study.
3.6. In vivo evaluation
Induction of ARF: ARF was induced by intramuscular injection of
single dose of 50% hypertonic glycerol (8 ml/kg) into both the hind
limbs in equal volume as per the standard methods prescribed.30,31
3.7. Experimental design
Rats were divided into 5 groups of 6 animals in each. Group 1
was treated with normal saline (10 ml/kg) per oral, group 2 with
single dose of hypertonic glycerol (8 ml/kg) by intramuscular in-
jection into both the hind limbs, group 3 with glycerol and ATR
extract 250 mg/kg, group 4 with glycerol and ATR extract 500 mg/
kg and group 5 was treated with ATR extract 500 mg/kg alone. The
ATR extract was given by oral route 60 min prior to glycerol in-
jection. The animals were observed for general behavior and ac-
tivity. Urine output was measured for all the animals for 24 h.
After 24 h, the blood samples were collected by retro orbital
sinus puncture and tested for serum creatinine, blood urea nitro-
gen, total proteins and albumin. All the levels were measured usingdiagnostic kits.32 The animals were then sacriﬁced by exposure to
halothane. The kidneys were isolated immediately and sent for
histopathological examination.
3.8. Estimation of antioxidant activity
The homogenized kidney was used for estimation of antioxi-
dants. The antioxidants, superoxide dismutase (SOD),33 reduced
glutathione (GSH),34 glutathione reductase (GR),35 glutathione
peroxidase (GPx),36 and catalase (CAT)37 were determined using
standard methods prescribed.
3.9. Histopathology
Kidneys were rinsed with normal saline and then ﬁxed in 10%
neutral buffered formalin solution, embedded in parafﬁn and used
for histopathological examination. The sections were 2 mm thick,
deparafﬁnized, hydrated and stained with haematoxylin and eosin.
The renal sections were examined for the extent of damage to
glomeruli, tubules and interstitium as well as for capillary
congestion and hemorrhage.
3.10. Statistical analysis
The data were expressed as mean ± S.E.M. One way analysis of
variance (ANOVA) traced by Tukey's multiple range test was
applied to calculate the statistical signiﬁcance among different
groups. P < 0.05 was considered to be statistically signiﬁcant.
4. Results
4.1. HPTLC proﬁle
The results from HPTLC ﬁnger print scanned at wavelength
254 nm for ethanolic extract of ATR showed 15 polyvalent phyto-
constituents (Graph) and corresponding retarding fraction (Rf),
height, area and lambda max (Table 1).
4.2. In vitro antioxidant activity
Ethanolic extract of A. tetracantha root in graded concentrations
was tested for antioxidant activity in four different in vitromethods
and compared with the standard antioxidant, vitamin C.
4.2.1. DPPH assay
Percentage of inhibition of DPPH radicals by different concen-
trations of ATR extract was 46% at 25 mg/ml and 89% at 1600 mg/ml.
Standard drug vitamin- C showed 50 % inhibition at 25 mg/ml and
95% at 1600 mg/ml (Table 2).
4.2.2. NO assay
The percentage inhibition of NO by ATR extract was 24% at
25 mg/ml and 91% at 1600 mg/ml. Vitamin-C showed 28 % and 95%
inhibition at 25 and 1600 mg/ml respectively (Table 3).
4.2.3. H2O2 assay
ATR extract showed 23% and 88% at 25 and 1600 mg/ml and
vitamin C at the same concentration showed 28 and 99% of
inhibition (Table 4).
4.2.4. FRAP assay
ATR extract had shown 22% inhibition at 25 mg/ml and 87% in-
hibition at 1600 mg/ml. Vitamin-C showed 28 % and 98% inhibition
at 25 and 1600 mg/ml respectively (Table 5).
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Nephroprotective activity was assessed by the levels of serum
creatinine, blood urea nitrogen, total proteins, albumin and urine
output as well as histopathological changes (Table 6).
Increased levels of serum creatinine, BUN and decreased total
proteins, albumin and urine output in glycerol treated animals
were seen (group 2) compared with normal saline treated animals
(group 1) conﬁrming renal failure. In ATR extract treated groups
there was a signiﬁcant decrease (p < 0.05) in serum creatinine,
blood urea nitrogen and increase in total proteins, albumin and
urine output at both the doses of 250 and 500 mg/kg. The group
treated with ATR extract alone (group 5) did not show any change
in the above parameters. (Fig. 1, biochemical parameters).
4.4. Enzymatic antioxidants
SOD, GSH, GR, GPx and CAT levels were signiﬁcantly (p < 0.05)
increased in group 3 and 4 compared with group 2. ATR extract at500 mg/kg had shown higher antioxidant levels than 250 mg/kg
(Fig. 2, in vivo antioxidant activity).4.5. Histopathology
Rat kidney in the control group had shown normal glomeruli
with intact Bowman's capsule, normal proximal convoluted and
distal convoluted tubules and there was no capillary congestion or
hemorrhage (group 1). Severe distortion of glomeruli, capillary
congestion, hemorrhages and apical blebbing were seen in glycerol
treated group indicating renal damage. In group 3 and 4, treated
with 250 and 500 mg/kg of ATR extract showed markedly reduced
capillary congestion, tubular damage and glomerular distortion
compared to glycerol treated group. The protective effect was found
to be better with 500mg/kg than 250mg/kg. Group 5 animals were
not sacriﬁced as they did not show abnormalities in biochemical
parameters. The histopathological changes were found to be in
correlation with biochemical changes. (Fig. 3, histopathology).
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The present study has evaluated the effect of A. tetracantha root
extract in glycerol-induced acute renal failure and its antioxidant
potential both in vitro and in vivo.
Glycerol-induced acute renal failure is one of the commonest
animal models used for evaluation of nephroprotective activity.30,31
The mechanisms involved in glycerol-induced renal failure include
oxidative stress, inﬂammation and apoptosis38,39 which lead to
rhabdomyolysis resulting in myoglobinemia, myoglobinuria and
cast formation.40 Cast formation causes tubular obstruction and
reduced GFR. Rhabdomyolysis causes cytokine activation and
release of inﬂammatorymediators such as IL-1, ICAM-1 and TNFa.41
These pro-inﬂammatory cytokines mediate the inﬂammatory re-
action causing afferent and efferent renal arteriolar vasoconstric-
tion42 eventually leading to renal failure. In general, about 10e40%
of patients with rhabdomyolysis develop ARF.43As oxidative stress and inﬂammatory damage have been mainly
attributed to the development of acute kidney injury, any com-
pound or drug having antioxidant& anti-inﬂammatory activity will
have a protective action against renal damage.
In our study ATR extract has shown a protective effect evi-
denced by its inhibition of alteration of renal biochemical pa-
rameters and reversal of histopathological changes. Prior
administration of ATR extract has caused reduction in serum
creatinine, blood urea nitrogen and increase in total proteins and
albumin. In addition the urine output increased in ATR treated
animals. The histopathological examination has shown signiﬁ-
cant reduction in cellular inﬁltration, capillary congestion,
glomerular damage, tubular necrosis and cast formation induced
by glycerol.
The possible mechanisms for the nephroprotective effect of ATR
extract could be due to the antioxidant and anti-inﬂammatory
actions.
Fig. 3. Histopathology. The kidney sections are shown in 10 magniﬁcation stained with haematoxylin and eosin. Group 1, Normal kidney: Normal kidney with glomerulus (G),
intact Bowman's capsule, proximal convoluted tubules (PCT) and distal convoluted tubules (DCT). No capillary congestion, hemorrhage and interstitial damage (I). Group 2, Glycerol
treated kidney: The arrows show several ruptured glomeruli, undeﬁned proximal, distal convoluted tubules, interstitial damage, capillary congestion and hemorrhages. Group 3,
Glycerol þ ATR extract 250 mg/kg: Picture shows intact glomeruli with Bowman's capsules, deﬁned proximal, distal convoluted tubules with less interstitial damage, capillary
congestion and hemorrhages. Group 4, Glycerol þ ATR extract 500 mg/kg: Many intact glomeruli with well deﬁned tubules and resolving interstitial damages show marked
protection in this group.
Table 1
HPTLC proﬁle of ethanolic extract of ATR.
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in vivo assays. The in vivo antioxidant effect of ethanolic extract ATR
on the levels of SOD, GSH, GPx, GR and CAT is shown in Fig. 2.
Glycerol treatment has reduced the levels of these antioxidants,
which get utilized in scavenging the free radicals generated during
glycerol-induced oxidative damage of renal parenchyma. ATRGraph. HPTLC proﬁle of ethanolic extract of ATR.
S. No Rf Height Area Lambda max
1 0.03 18.0 249.6 297
2 0.04 9.4 75.6 297
3 0.07 6.8 69.1 287
4 0.12 21.3 535.1 205
5 0.17 15.8 152.9 266
6 0.18 12.5 116.7 267
7 0.22 8.0 88.3 207
8 0.23 6.0 37.2 210
9 0.26 8.0 181.7 294
10 0.36 2.8 54.9 213
11 0.48 2.8 67.2 213
12 0.55 4.3 109.1 215
13 0.71 14.4 622.4 299
14 0.78 9.0 398.7 219
15 0.89 13.7 706.0 214
In vitro antioxidant activity.
Table 2
DPPH scavenging activity.
Percentage inhibition of ATR extract and Vitamin-C
Concentration mg/ml ATR extract Vitamin-C
25 46.33 ± 1.45 50.99 ± 0.57
50 67.32 ± 1.15 70.00 ± 0.57
100 73.23 ± 0.88 77.33 ± 1.20
200 78.32 ± 0.33 81.99 ± 0.57
400 85.31 ± 0.57 88.00 ± 0.59
800 87.36 ± 0.66 93.66 ± 0.33
1600 89.33 ± 0.33 95.37 ± 0.57
Values were expressed as Mean ± SEM, n ¼ 3.
Table 3
NO scavenging activity.
Percentage inhibition of ATR extract and Vitamin-C
Concentration mg/ml ATR extract Vitamin-C
25 24.33 ± 0.88 28.66 ± 0.33
50 51.33 ± 2.60 56.33 ± 0.57
100 77.33 ± 1.20 79.33 ± 0.33
200 87.00 ± 0.57 86.33 ± 1.20
400 89.66 ± 0.66 90.66 ± 0.33
800 90.66 ± 0.33 91.33 ± 0.33
1600 91.66 ± 0.33 94.95 ± 0.88
Values were expressed as Mean ± SEM, n ¼ 3.
Table 4
H2O2 scavenging activity.
Percentage inhibition of ATR extract and Vitamin-C
Concentration mg/ml ATR extract Vitamin-C
25 23.33 ± 0.88 29.66 ± 2.33
50 36.66 ± 1.20 43.66 ± 0.66
100 72.33 ± 0.33 84.33 ± 1.20
200 79.66 ± 0.88 88.00 ± 0.57
400 83.66 ± 0.68 88.33 ± 1.20
800 85.66 ± 0.66 90.66 ± 1.20
1600 88.33 ± 0.62 98.12 ± 0.26
Values were expressed as Mean ± SEM, n ¼ 3.
Table 5
FRAP scavenging activity.
Percentage inhibition of ATR extract and Vitamin-C
Concentration mg/ml ATR extract Vitamin-C
25 22.33 ± 0.83 28.33 ± 1.33
50 35.99 ± 1.20 44.66 ± 0.66
100 70.33 ± 0.22 83.33 ± 1.22
200 75.66 ± 0.66 87.22 ± 0.57
400 80.66 ± 0.99 89.33 ± 1.20
800 84.66 ± 0.66 91.66 ± 0.20
1600 87.33 ± 0.62 98.12 ± 0.26
Values were expressed as Mean ± SEM, n ¼ 3.
Table 6
Effect of ATR extract on biochemical parameters & urine output.
Values are mean ± SEM
Parameters Groups
Control Glycerol (G) GþATR (250 m
Creatinine (mg/dl) 0.71 ± 0.02 4.18 ± 0.07 1.73 ± 0.13
BUN (mg/dl) 17.8 ± 0.19 52.2 ± 0.34 26.8 ± 0.23
Total proteins (g/dl) 6.10 ± 0.10 2.03 ± 0.18 3.31 ± 0.21
Albumins (g/dl) 5.01 ± 0.19 1.86 ± 0.19 3.21 ± 0.09
Urine output (ml) 7.43 ± 0.17 3.36 ± 0.13 5.65 ± 0.11
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dependent increase in the level of the antioxidants. The importance
of protecting the antioxidants pool in preventing renal damage has
been emphasized by Singh et al.44 The in vitro antioxidant effect
exhibited in different assays has further supported the antioxidant
property of ATR extract.
The phytochemicals found to be present in the root extract are
the ﬂavonoids, terpinoids, alkaloids, tannins, saponins & glucosi-
nolates.45,46 Among them tannins, triterpinoids, ﬂavonoids and
saponins could be responsible for antioxidant property as these
phytoconstituents are already reported to have antioxidant activity.
The anti-inﬂammatory activity could be due to the presence of
ﬂavonoids which are well known to have anti-inﬂammatory action.
The root extract also contains tannins. Tannins have vasodilatory
activity.47 Renal vasodilatation can improve the GFR and urine
output. This could be a reason for using ATR extract as a diuretic
agent in traditional systems. Hence terpinoids, tannins and ﬂavo-
noids present in the root extract may have contributed to the
protection from renal damage induced by glycerol by their anti-
inﬂammatory, antioxidant and vasodilatory as well as diuretic
actions.
The extract of AT leaves has been found to have ant-
inﬂammatory activity.20 The leaves contain freidelin which is a
terpinoid. Freidelin has been established to have antioxidant, free
radical scavenging, hepato-protective48 ant-inﬂammatory, anal-
gesic and antipyretic activities.49 Beta sitosterol, also a terpinoid
has been reported to have antipyretic and anti-inﬂammatory ac-
tivity.50 The terpinoids in the roots can similarly produce these
actions.
The glucosinolate and N-hydroxy-3-indolylmethyl-glucosino-
late were detected in ATR and not in the other parts of the plant.24
Glucosinolates have vasodilatory effect like tannins and ﬂavo-
noids.51,52 Renal vasodilatation by these components can improve
renal blood ﬂow, reduce the ischemic changes and also increase
urine output.
Thus the in vitro and in vivo ﬁndings suggest that protection
from oxidative damage, anti-inﬂammatory and vasodilatory actions
of the various phytochemicals present in ATR extract could have
contributed to the nephroprotective actions of A. tetracantha root
extract in acute renal failure. Between the 2 doses administered,
250 and 500 mg/kg, 500 mg/kg is found to have signiﬁcant neph-
roprotective action.
6. Conclusion
The ethanolic extract of ATR is found to have nephroprotective
effect in glycerol-induced acute renal failure in Wistar albino rats.
ATR extract is found to have signiﬁcant action at 500 mg/kg
compared to 250 mg/kg. The possible mechanisms could be the
antioxidant, anti-inﬂammatory, vasodilatory and diuretic activity of
its phytochemical constituents such as ﬂavonoids, terpinoids, tan-
nins, glucosinolate and saponins.g/kg) GþATR (500 mg/kg) ATR (500 mg/kg) P -value
0.71 ± 0.08 0.72 ± 0.01 0.0001
18.2 ± 0.19 17.8 ± 0.34 0.0001
5.28 ± 0.16 6.40 ± 0.09 0.001
4.66 ± 0.20 4.95 ± 0.19 0.001
7.45 ± 0.07 8.16 ± 0.16 0.001
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